ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2025 Earnings Conference Call August 13, 2025 2:00 PM ET Company Participants Ted William Karkus - Chairman & CEO Operator Welcome to today's presentation. My name is Noella Alexander-Young, virtual event moderator here at Renmark Financial Communications.
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 720 | $324 | $72 | -$252 | -77.78% |
Christopher C. Powers Farther Finance Advisors, LLC | 9 | $4 | $0.9 | -$3.1 | -77.5% |
| Specialty Retail Industry | Consumer Discretionary Sector | Ted William Karkus CEO | OTC PINK Exchange | 74345W108 CUSIP |
| US Country | 96 Employees | 3 Jun 2022 Last Dividend | 22 Dec 2025 Last Split | 16 Jan 1997 IPO Date |
ProPhase Labs, Inc., initially known as The Quigley Corporation, is a company dedicated to the development and commercialization of novel drugs, dietary supplements, and various compounds within the United States. The company has diversified its operations into two main segments: Diagnostic Services and Consumer Products, offering a broad spectrum of services and products ranging from health supplements to diagnostic services. Founded in 1989, ProPhase Labs has established its headquarters in Garden City, New York, indicating a longstanding presence and experience in the healthcare and consumer products sectors.
Among its range of products, ProPhase Labs offers TK supplements targeted at enhancing male sexual health under the brand Legendz XL, and Triple Edge XL, aimed at boosting energy and stamina. These products reflect the company's focus on addressing specific health and wellness needs through over-the-counter (OTC) consumer healthcare products.
The company extends its expertise by offering comprehensive contract manufacturing services, which encompass product development, pre-commercialization, production, warehousing, and distribution. This suite of services supports other businesses in bringing their health and wellness products to market efficiently.
Providing COVID-19 diagnostic information services has positioned ProPhase Labs as a crucial entity during and beyond the pandemic, catering to a diversified clientele including health plans, third-party payers, and government organizations. The company also offers respiratory pathogen panel molecular testing services, underscoring its capability in diagnosing a range of viral and bacterial infections alongside its COVID-19 testing.
Expanding into the personal genomics space, ProPhase Labs delivers products and services that allow individuals to explore their genetic information. This initiative signifies the company’s commitment to leveraging advanced technologies for enhancing personal health and wellness.
The final aspect of ProPhase Labs’ operations involves the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements. This range underscores the company’s extensive involvement in the consumer healthcare sector, catering to various customer needs from prevention to treatment.